Rules-Based Medicine (RBM)
Rules-Based Medicine (RBM), an IQVIA business, brings 25 years of expertise in developing multiplexed immunoassays for translational and clinical research. Our CNS menu includes internally developed Simoa-based assays: beta amyloid 40 and 42; pTau 181, 217 and 231; alpha-synuclein, neurofilament light chain and neurofilament heavy polypeptide. Our newest offering is the Alamar NULISAseq CNS disease panel 120, delivering highly reproducible assays with attomolar sensitivity. We also offer Olink Target 48 and 96 neurology panels.
